FAST-EU opened a narrowly defined accelerated review route on November 10, 2026, for substantial modifications needed to resolve approval conditions blocking the start of an existing FAST-EU clinical trial. The change gives university and other trial sponsors a faster assessment pathway for that specific obstacle, according to the Heads of Medicines Agencies.
November opening targets conditions that prevent trial initiation
The HMA notice says sponsors can contact the reporting Member State about eligible modifications from November 10. FAST-EU is run by HMA, the Clinical Trials Coordination Group and MedEthics EU within the EU Clinical Trials Regulation and CTIS framework.
The current Sponsor Guide, version 1.3 dated November 2, covers Part I and/or Part II modifications addressing conditions that currently prevent initiation of a trial already approved through FAST-EU. Modifications unrelated to conditions and subsequent additions of Member States are excluded.
Portugal’s medicines regulator, Infarmed, announced the expansion on November 5, describing its application from November. The November 10 opening therefore concerns operational access to the extension, rather than the original launch of FAST-EU earlier in 2026.
The modification pathway has a six-week assessment target
Chapter 9 of the Sponsor Guide sets out the accelerated sequence. Sponsors should notify both the FAST-EU Coordination Office and the reporting Member State one week before planned CTIS submission. The cover letter should identify the condition-related application and explain that changes are restricted to those requested to lift the condition.
| Milestone | Target after submission |
|---|---|
| Validation decision | Day 21 |
| Sponsor response to assessment requests | Day 35 |
| Part I and Part II conclusions | Day 42 |
These are calendar-day coordination targets within the existing legal framework. National decisions follow under CTR and CTIS timelines; the guide identifies five calendar days. The 42-day assessment target consequently should not be presented as a guaranteed trial-start date or an automatic authorisation.
Existing CTIS requirements still shape the submission
The European Medicines Agency’s CTIS Sponsor Handbook distinguishes Part I-only, Part II-only and combined substantial-modification applications. A Part II-only application concerns one Member State at a time, while a combined Part I and Part II submission can involve several. Sponsors remain responsible for judging whether a change is substantial, case by case.
The handbook also explains that a sponsor can submit a modification only to a Member State where the trial is authorised and where an assessment of the same dossier part is not already ongoing, subject to the stated parallel-assessment arrangements. For university teams coordinating several national submissions, the practical implication is that eligibility for FAST-EU and the application’s current CTIS status both matter.
The Norwegian Medical Products Agency’s modification guidance requires a cover letter and modification description, dated and versioned documents, clean and tracked versions, and updates to affected CTIS structured data. That documentation connects the approved dossier to the proposed change, including a protocol amendment where applicable.
That agency defines a substantial change by its likely impact on participants’ safety or rights, or on the reliability and robustness of trial data. The classification concerns the substance of the change, beyond its administrative label.
Portugal reports participation in 13 selected trials
Infarmed reported that 38 trials had been selected for accelerated assessment across the EU and European Economic Area, with Portugal participating in 13. Portugal was the reporting Member State for two and a concerned Member State for the other 11. Those figures describe participation in the pilot; they do not measure results from the newly opened modification route.
HMA’s status update records 158 expressions of interest and says participating states agreed to accept more applications than initially planned in response to demand.
In its November 11 report, independent health-sector outlet NXTin described the extension as a further stage of FAST-EU and highlighted Portugal’s involvement in roughly one-third of selected trials. The report drew on Infarmed’s announcement. Infarmed framed the expansion as a way to shorten the regulatory stages associated with starting trials.
What changes for university research offices
For an academic sponsor, the immediate significance is the link between a specific unresolved approval condition and the documents needed to remove it. A broader programme of amendments cannot be assumed to qualify merely because the original trial entered FAST-EU. The distinction matters when research offices coordinate regulatory staff, investigators and national partners around a planned start.
The Norwegian guidance separately explains that changes can be substantial, non-substantial but relevant to regulatory supervision, or neither. It places responsibility for that assessment on the sponsor and requires continuous documentation of non-substantial changes in the trial master file. Accelerated handling therefore sits alongside established change classification and documentation duties.
Next initial-trial entry window is November 19–20
Separately, HMA lists November 19–20 as the expression-of-interest window for the December 2026 initial-trial round, with responses on November 27. That calendar concerns entry of new trials into the voluntary, capacity-limited pilot. Sponsors seeking condition-related modifications use the newly opened route through their reporting Member State.
Sources
- Heads of Medicines Agencies: Clinical Trials Coordination Group, FAST-EU notice and submission calendar, checked 2026-11-17.
- CTCG and MedEthics EU: FAST-EU External Guidance for Sponsors, version 1.3, November 2, 2026; checked 2026-11-17.
- Infarmed: FAST-EU alarga avaliação acelerada a alterações substanciais nos ensaios clínicos, November 5, 2026; checked 2026-11-17.
- NXTin: Portugal involved in one-third of clinical trials selected for Europe’s FAST-EU initiative, November 11, 2026; checked 2026-11-17.
- European Medicines Agency: CTIS Sponsor Handbook, section 4.3, checked 2026-11-17.
- Norwegian Medical Products Agency: Application for Substantial Modifications in Clinical Trials of Medicinal Products for Human Use, checked 2026-11-17.







